Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/12871
Full metadata record
DC FieldValueLanguage
dc.contributor.authorJackson, Ben
dc.contributor.authorCubela, R Ben
dc.contributor.authorConway, Elizabeth Len
dc.contributor.authorJohnston, Colin Ien
dc.date.accessioned2015-05-16T02:37:14Z
dc.date.available2015-05-16T02:37:14Z
dc.date.issued1988-06-01en
dc.identifier.citationBritish Journal of Clinical Pharmacology; 25(6): 719-24en
dc.identifier.govdoc2849471en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/12871en
dc.description.abstract1. Lisinopril, a new orally active angiotensin converting enzyme inhibitor, was given to eight patients with stable chronic renal failure, in a dose of 5 mg 24 h-1 for 1 week. Creatinine clearance of the subjects ranged from 0.22 to 1.11 ml s-1. Lisinopril pharmacokinetics were studied over 8 days. 2. There was a close correlation between creatinine clearance and total 'area under the curve' over the 8 days of study (r = -0.88, P less than 0.05), and plateau lisinopril concentration and creatinine clearance (r = -0.77, P less than 0.05). 3. Serum angiotensin converting enzyme activity was inhibited in proportion to log serum lisinopril concentration (r = -0.99, P less than 0.001). Calculated IC50 was 47 ng lisinopril ml-1. from pooled data, with individual patients IC50 ranging from 20 to 70 ng lisinopril ml-1. 4. Creatinine clearance was unaltered by treatment. Serum potassium rose to over 5 mmol 1-1 in four patients, without adverse clinical effect.en
dc.language.isoenen
dc.subject.otherAdulten
dc.subject.otherAgeden
dc.subject.otherAngiotensin-Converting Enzyme Inhibitors.pharmacokinetics.therapeutic useen
dc.subject.otherBlood Pressure.drug effectsen
dc.subject.otherCreatine.blooden
dc.subject.otherEnalapril.analogs & derivatives.blood.pharmacokinetics.therapeutic useen
dc.subject.otherFemaleen
dc.subject.otherHumansen
dc.subject.otherKidney Failure, Chronic.drug therapy.metabolismen
dc.subject.otherLisinoprilen
dc.subject.otherMaleen
dc.subject.otherMiddle Ageden
dc.subject.otherPeptidyl-Dipeptidase A.metabolismen
dc.subject.otherProteinuria.urineen
dc.subject.otherPulse.drug effectsen
dc.titleLisinopril pharmacokinetics in chronic renal failure.en
dc.typeJournal Articleen
dc.identifier.journaltitleBritish journal of clinical pharmacologyen
dc.identifier.affiliationUniversity of Melbourne, Department of Medicine, Austin Hospital Heidelberg, Victoria, Australiaen
dc.description.pages719-24en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/2849471en
dc.type.austinJournal Articleen
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.languageiso639-1en-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
crisitem.author.deptGastroenterology and Hepatology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

6
checked on Jan 27, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.